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Abstract
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder 
in reproductive-aged women. Clinical or biochemical signs of androgen excess is a 
cardinal feature of the syndrome and are present in approximately 80% of women 
with PCOS. Increased blood pressure and insulin resistance, two major cardio-
vascular risk factors, are frequently present in women with PCOS. This chapter 
aims to highlight the fundamental role of androgens in mediating the increased 
blood pressure and insulin resistance in women with PCOS. This chapter is also a 
call for action to develop new pharmacological therapies that target the androgen 
synthesis and androgen receptor activation dysregulation present in women with 
PCOS. These novel therapies will allow to prevent or mitigate the excess androgen-
mediated cardiovascular risk factors that affect women with PCOS.
Keywords: polycystic ovary syndrome, androgens, androgen receptor,  
blood pressure, insulin resistance
1. Introduction
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder 
and cause of androgen excess in reproductive-age women [1, 2]. The etiology of 
the syndrome is unknown, and the pathophysiological characteristics are complex. 
There are three different sets of diagnostic criteria available to diagnose PCOS; the 
Rotterdam criteria is the most commonly used. The key difference among those 
three criteria is that hyperandrogenism is considered an essential component of the 
syndrome for the Androgen Excess Society guidelines [3] and National Institutes 
of Health (NIH) [4], but not for the Rotterdam criteria [5]. More recently, the 
Rotterdam criteria for PCOS diagnosis were endorsed by the NIH at an NIH-
sponsored workshop [6] as well as by the International evidence-based guideline for 
the assessment and management of PCOS [7]. Insulin resistance (IR) is frequently 
present in lean and obese women with PCOS, but it is not included in the diagnostic 
criteria. Women with PCOS may seek medical care due to a broad range of clinical 
manifestations such as infertility, menstrual dysfunction, excessive hair growth or 
hirsutism, alopecia, or acne. More recently, it became clear that the cardiometabolic 
risk factors, such as IR, increases in blood pressure (BP), and obesity affect a high 
percentage of women with PCOS compared to normal cycling women [8–11]. 
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Importantly, in women with PCOS, plasma levels of androgens positively correlate 
with BP and IR. Whether and how androgen excess causes increased BP and IR in 
women with PCOS is unknown. Unfortunately, limited effective evidence-based 
therapeutic agents are available to treat those cardiovascular risk factors in PCOS 
patients. Furthermore, the use of antiandrogens in PCOS is often only recom-
mended to manage the dermatological manifestations of the syndrome, but neither 
the IR nor increases in BP [12]. This chapter aims to highlight the fundamental role 
of androgens in mediating increases in BP and IR in women with PCOS and the lack 
of therapeutic options to ameliorate the hyperandrogenism and cardiometabolic 
complications in these patients.
2. Androgen synthesis in PCOS
In women, the concentration of plasmatic androgens is higher than of estrogens 
[13]. Excess androgens are secreted by the ovaries in most women with PCOS, 
but in 20–30% of them, excess androgens are also secreted by the adrenal gland. 
Plasma levels of total and free testosterone (T), dihydrotestosterone (DHT), 
dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS), and androstenedione 
are significantly elevated in PCOS [2, 14]. Androstenedione, DHEA, and DHEAS 
are pro-hormones synthesized by the adrenal gland, they circulate at a higher 
concentration than T. Those pro-hormones could be converted into more potent 
T and DHT in the adipose tissue, liver, and the skin [3, 15]. Depending on the 
type of androgens measured, hyperandrogenemia is present in ~80% of PCOS 
diagnosed cases [16]. Recently, a study showed that the 11-oxygenated androgens, 
11β-hydroxyandrostenedione, 11-ketoandrostenedione, and 11-ketotestoster-
one, represent the majority of circulating androgens in women with PCOS [17]. 
Moreover, 11β-hydroxyandrostenedione, 11-ketoandrostenedione circulating levels 
positively correlate with circulating insulin and IR assessed by the Homeostatic 
Model Assessment of Insulin Resistance (HOMA-IR) in women with PCOS [17]. 
The HOMA-IR is an index of IR calculated according to the formula: fasting insulin 
(microU/L) x fasting glucose (nmol/L)/22.5 [18]. The HOMA-IR is extensively 
used in epidemiological studies, but rarely in the clinical setting. On the other 
hand, the hyperinsulinemic eulgycemic clamp is considered the gold standard to 
determine IR; but, unfortunately, it is impractical for routine use in the clinic [19]. 
Local production or activation of androgens at the tissular level have been reported, 
and they may constitute a key factor in the cardiometabolic abnormality in these 
patients. For example, the subcutaneous adipose tissue in women with PCOS has a 
higher concentration of androgens than in control subjects [20, 21]. Testosterone 
can be converted to its more biologically active form, DHT, by the 5α-reductase, and 
to estradiol by the aromatase. DHT is more biologically active than testosterone, 
binding to the androgen receptor (AR) with a 2-fold higher affinity and a 5-fold 
decreased dissociation rate compared to testosterone [22]. The synthesis of andro-
gens in women is complex. The local activation of androgens is not well understood 
during normal physiology or diseases such as PCOS.
3. Androgen receptor in PCOS
AR is a member of the steroid hormone receptor superfamily, a class of receptors 
that function through their ability to regulate the transcription of specific genes. 
It contains an N-terminal transactivation domain, a central DNA-binding domain, 
and a C-terminal ligand-binding domain [23]. Androgens act by binding to the 
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AR and subsequently translocate to the nucleus to act as a transcription factor and 
promote gene expression. The unbound AR is inactive in the cytoplasm as a large 
dynamic heterocomplex, together with heat shock proteins (Hsp70 and Hsp90) 
and their co-chaperones [24]. Ligand binding dissociates the AR from heat shock 
proteins, causing its activation and translocation to the nuclei to exert its transcrip-
tion regulatory role.
Androgen actions in the cardiovascular system could be genomic or non-
genomic [25], although most of the basic research data available derived from 
experiments performed in male rats. The activity of AR is modulated by a poly-
glutamine tract of variable size in its N-terminal transactivation domain. This 
polyglutamine tract is encoded by a highly polymorphic CAG repeat sequence in 
exon 1 of the AR gene located on the X-chromosome. Shorter CAG repeats lengths 
in exon 1 of the AR gene are associated with a stronger transcriptional activity of 
the AR. The shorter CAG repeats have been associated with the androgen actions 
in male conditions such as prostate cancer [24] and benign prostatic hyperplasia 
[26]. Moreover, abnormal expansion of the CAG repeat length leads to Kennedy’s 
disease, which is associated with hypogonadism and impaired spermatogenesis in 
men [27, 28]. However, studies in women with PCOS did not find significant dif-
ferences in the mean values of CAG repeat sizes compared to controls [29, 30]. The 
fundamental role of AR in the development of metabolic and reproductive features 
of PCOS was demonstrated by the lack of effect of DHT in AR knockout (ARKO) 
mice, supporting the fundamental concept that androgen excess, via AR activation, 
is a key factor in PCOS [31]. More recent studies further demonstrated that AR 
signaling pathways within the brain and adipocytes are key in the physiopathology 
of metabolic PCOS characteristics [32]. Pharmacological strategies safely targeting 
the brain and adipocyte AR-could constitute a novel and effective way to ameliorate 
the cardiometabolic complications in PCOS.
4. Cardiovascular disease in PCOS
Several studies have shown that the odds ratio for cardiovascular disease (CVD) 
is significantly higher in women with PCOS compared to the control women 
[33–35]. Whether women with PCOS suffer from higher mortality from CVD is 
still unclear, pending high-quality data. Obesity is frequently observed in women 
with PCOS, but, even after BMI adjustment, the increased risk for cardiovascular 
events in PCOS persists, suggesting that additional factors play a role in mediating 
the higher prevalence of CVD in women with PCOS [35]. Hypertension, the most 
important modifiable cardiovascular risk factor for cardiovascular disease, is com-
monly diagnosed in women with PCOS. Moreover, insulin resistance, another risk 
factor for CVD, is also frequently present in women with PCOS, and independent 
of those subjects’ BMI. Data from clinical and basic research suggest that hyperan-
drogenism may underlie these cardinal cardiovascular risk factors in patients with 
PCOS. Below we describe whether and how androgens mediate the increases in BP 
and IR in women with PCOS.
5.  Hyperandrogenism is a key factor mediating increases in blood 
pressure in women with PCOS
Increased BP remains the leading risk factor for death globally, accounting 
for 10.4 million deaths per year [36]. There is a sexual dimorphic relationship 
between androgens and BP in women compared to men. Free androgen index 
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(FAI), a measure of bioavailable androgens, is positively correlated with systolic 
and diastolic blood pressure [37]. A recent meta-analysis reported a greater risk of 
developing hypertension in reproductive age women with PCOS [38]. In contrast, 
epidemiological studies have shown an inverse relationship between androgens 
and BP in men, and this association persisted after adjusting for age and body 
mass index [39]. The mechanisms behind the elevated BP in response to hyperan-
drogenism in women remain unclear. Some of the possible mechanisms involved in 
androgen-mediated regulation of BP are discussed below.
6.  Potential mechanisms that could mediate increases in blood pressure 
in PCOS
The kidneys are a key regulator of long-term BP control and body fluid homeo-
stasis in the body. The renin-angiotensin-aldosterone system (RAAS) plays a 
major role in several forms of hypertension, and it is composed of the classical and 
non-classical arms with opposite physiological effects [40, 41]. The classical RAS 
pathway starts with angiotensinogen (AGTN) which is enzymatically cleaved to 
Angiotensin I (ANG I) by renin. ANG I is then cleaved by angiotensin I converting 
enzyme (ACE) to Angiotensin II (ANG II), which binds to the ANG II receptor 
type 1 (AT1R) and ANG II type 2 receptor (AT2R). High levels of ANG II had been 
related to metabolic disorders. The non-classical pathway, the angiotensin I con-
verting enzyme 2 (ACE2) reduces Ang II levels by transforming it in Angiotensin 
(1–7) (ANG (1–7)), which also can be generated from ANG I passing through 
Angiotensin (1–9) (ANG (1–9)) by the action of the endopeptidases: prolyl-
endopeptidase and neutral endopeptidase. The main known biological effects of 
ANG (1–7) are associated with Mas receptor activation, causing an improvement in 
metabolic syndrome, obesity, and hypertension.
The rate-limiting step of the RAS is the conversion of AGTN to ANG I by renin 
[42]. Women with PCOS have hyperreninemia [43], and blockade of the AT1R is 
effective in decreasing their BP [44]. We and others have shown that androgens 
stimulate the synthesis of intrarenal AGTN in male and female rats [45–48]. In the 
kidney, the AR is highly expressed in proximal tubule cells [49], glomerular endo-
thelial cells [50], and podocytes [51]. Moreover, the enzymes involved in androgen 
biosynthesis are expressed and active in the kidney [52]. In experimental models 
of hypertension, androgens can shift the pressure-natriuresis curve to the right, 
promoting sodium reabsorption [53, 54]. Androgens could also directly increase 
sodium reabsorption via upregulation of epithelial sodium channel (ENaC) α, β, 
and γ subunits expression [55]. Renal medullary blood flow and the sensitivity of 
the pressure-natriuresis response are regulated by various paracrine and humoral 
factors known to play an important role in the control of renal function and BP. 
Those regulatory factors include ANG II, kinins, prostaglandins, atrial natriuretic 
peptide (ANP), and nitric oxide (NO). Whether changes in the renal medulla 
microcirculation play a role in mediating the increases in BP under excess of andro-
gens in women with PCOS remains unclear.
Plasma ACE2 activity is low in healthy subjects but elevated in patients with 
cardiovascular risk factors or cardiovascular disease. Hypertensive men have a high 
higher level of plasma ACE2 compared to women [56]. The role of increased levels 
of plasmatic ACE2 in men remains unknown. It has been reported that male mice 
have higher renal ACE2 mRNA and protein expression, as well as higher ACE2 
activity, than their female counterparts [57, 58]. However, the effect of androgen 
excess in the non-classical RAS pathway is still not well understood. Androgens 
downregulate AT2R expression levels in the aorta, in vivo, and ex vivo [59]. ACE2 is 
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the receptor for SARS-CoV and SARS-CoV-2 [60, 61]. SARS-CoV and probably 
SARS-CoV-2, Spike protein binding to the ACE2 receptor causes its downregulation 
through internalization [62]. SARS-CoV causes an imbalance in ACE/ACE2 and 
consequently ANG II/ANG (1–7) that leads to lung injury [62]. Men have suffered 
a higher rate of severity and mortality from COVID-19 [63]. Whether such sex 
difference in COVID-19 outcomes is due to ACE2 expression modulation by andro-
gens remains unknown. Further research is needed to elucidate whether and how 
androgens modulate the non-classical RAS pathway in PCOS and how its regulation 
could impact COVID-19 outcomes in this population.
Our research teams’ studies focus on the cardiometabolic complications associ-
ated with androgen excess in female rats. The hyperandrogenic female (HAF) rat, 
an animal experimental model of PCOS, is generated by the chronic administra-
tion of the non-aromatizable androgen DHT. This model exhibits upregulation 
of intrarenal angiotensinogen and ACE mRNA expression, which are associated 
with a ~ 10 mmHg increase in BP compared to control female rats [46]. When 
HAF rats are treated with enalapril, an ACE inhibitor, their BP is lowered to values 
comparable to that of control rats, suggesting that the RAAS activation has a role in 
mediating androgens’ effect on BP [64]. The stimulatory effect of androgens upon 
the intrarenal RAAS persisted after discontinuation of androgen exposure in female 
rats, suggesting a cardiometabolic androgenic memory in female rats. Interestingly, 
in the kidney medulla, AGTN and AT1R were still elevated after six months of DHT 
withdrawal [65]. AT1R blockers or ACE inhibitors are widely used as antihyperten-
sive drugs. Women should be advised about the potential teratogenic and fetotoxic 
risks of ACE inhibitors or AT1R blockers if they become pregnant. ACE inhibitors 
and AT1R blockers use in the first trimester of pregnancy may not present signifi-
cant risks for malformations in live births but a high risk of miscarriage [66]. Novel 
and tissue-selective RAAS inhibitors that do not cross the placental barrier are 
warranted to ameliorate the increases in BP in women with PCOS in the future.
In the US, a frequent finding in PCOS patients is an increase in body mass index 
(BMI), with up to 80% being either overweight or obese [67]. There is a strong 
link between adiposity and hypertension, with multiple mechanisms being sug-
gested [68]. Hypertrophy of adipocytes is associated with local hypoxia, leading 
to increased oxidative stress and inflammatory cytokines, followed by capillary 
rarefaction [69, 70]. These processes can lead to a positive feedback loop, ultimately 
releasing more inflammatory cytokines and reactive oxidative species into the 
systemic circulation. Chronic inflammation can ultimately lead to increased BP. In 
HAF rats, there is increased fat mass and BP coupled with increased plasma tumor 
necrosis factor-alpha and renal mRNA expression of NADPH oxidase 4 [46, 71]. 
Increased adiposity is also associated with increased circulating adipokines, such 
as leptin [69]. Chronic hyperleptinemia is known to stimulate the sympathetic 
nervous system [72], which could lead to vasoconstriction. It has been reported that 
in women with PCOS, leptin levels can be elevated [73]. Furthermore, using heart 
rate variability as a measure of autonomic dysfunction, women with PCOS have 
increased sympathetic activity compared to control women matched for body mass 
index, systolic and diastolic BP [74]. Additionally, leptin is linked to activation of 
the RAAS via the renal sympathetic nervous system [72]. All the findings men-
tioned above suggest that BP control is complex and depends on multiples pathways 
in women with PCOS.
Endothelial dysfunction refers to the impaired function in the endothelium, 
the inner lining of blood vessels, which could lead to inappropriate vasoconstric-
tion and atherosclerosis [75]. Endothelial dysfunction frequently occurs under 
chronic inflammation conditions or high oxidative stress, which interfere with 
the nitric oxide production needed for vasodilation [76]. Interestingly, this occurs 
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not just in obese females but also in lean females with PCOS. A recent study found 
that normotensive lean females with PCOS, even without insulin resistance, had 
increased endothelial dysfunction compared to controls [77]. One of the major 
vascular oxygen-derived free radicals is superoxide anion. Superoxide is routinely 
scavenged by superoxide dismutase (SOD). Superoxide can also combine with nitric 
oxide (NO), which results in quenching of NO and, theoretically, can induce vaso-
constriction. There is an interaction between NO and oxidative stress to maintain 
endothelial function. We previously showed that an intact NO system is necessary 
for antioxidants to elicit a BP-lowering effect [78]. Furthermore, Huirliman and col-
leagues demonstrated that the presence of endothelial dysfunction and IR develops 
in pair-fed DHT-treated female rats, suggesting an obesity-independent mechanism 
[79]. Increased endothelial dysfunction has also been found in transgender men 
compared to cisgender women matched for body mass index [80], suggesting a 
broader link between endothelial dysfunction and female androgen excess in addi-
tion to women with PCOS. Another study with lean females with PCOS also found 
that they had decreased plasma total antioxidant status [81]. This reduced ability to 
handle oxidative stress can contribute to the endothelial dysfunction in hyperan-
drogenic females.
Cardiovascular diseases are the leading cause of death in women. Furthermore, 
there have been an overall decline in CVD mortality over the past 40 years; how-
ever, the mortality in younger women has plateaued since 2000 [82]. Increases 
in BP is a primary cardiovascular risk factor. The carotid artery intima-media 
thickness (cIMT) has emerged as an important surrogate marker of target organ 
damage in hypertensive heart disease. A recent prospective cross-sectional study in 
PCOS women showed that cIMT was significantly increased in women with PCOS 
compared to controls, and this increase was independent of BMI, age, and smoking 
status [83]. Consequenly, the cIMT could be used to determine the cardiovascular 
risk profile in women with PCOS.
In summary, hyperandrogenemia in females has multiple mechanisms of 
causing increased BP and impaired vascular function. Pharmacological agents that 
target multiple pathways could constitute effective therapeutic agents to be used in 
women with PCOS.
7.  Hyperandrogenism is a key factor mediating insulin resistance  
in PCOS
IR is recognized as a significant contributor to metabolic homeostasis distur-
bances in women with PCOS, especially in obese individuals, due to increased 
lipid accumulation in muscle and liver from impaired insulin signaling. Decreased 
insulin sensitivity and glucose tolerance have been reported in women with PCOS 
versus healthy individuals in several studies [84]. Additionally, both metabolic 
syndrome and hyperinsulinemia have a characteristic increase in low-grade inflam-
mation markers [85], which has also been observed in women with PCOS [86]. IR 
prevalence among women with PCOS is varied between different measurement 
methods but is reported to be between 40% and 70%, approximately [87]. Women 
with insulin receptor mutations, and thus high levels of insulin, develop severe 
hyperandrogenemia [88].
Hyperandrogenism and or hyperandrogenemia is present in about 80% of 
women with PCOS [89]. Both circulating testosterone and its precursor andro-
stenedione have been shown in positive association with the severity of metabolic 
dysfunction in women with PCOS [90]. The prevalence of type 2 Diabetes Mellitus 
(T2DM) in the US is 10-times higher among young women with PCOS compared to 
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age-matched, normal-cycling women [91]. Insulin and insulin signaling can influ-
ence androgens in women with PCOS. Insulin can stimulate the ovaries of theca 
cells to produce androgens. This dysfunctional androgen stimulation is suggested to 
induce hyperandrogenism in women with PCOS in a positive feedback mechanism 
with hyperinsulinemia. Specifically, the P450c17 (CYP17A1) enzyme in the theca 
cells has been addressed as having modulated activity in response to insulin and 
IGF. This is specifically relevant to PCOS because the enzyme is necessary for the 
production of androgens [92]. Additionally, high circulating plasma insulin may 
itself influence androgen availability due to its suppression of sex hormone-binding 
globulin (SHBG) synthesis, a steroid transport protein, and subsequent increase in 
the bioavailability of unbound testosterone [93]. PCOS patients have been shown 
to have reduced SHBG level [94], that could lead to increases in free T. In addition 
to its role in glucose homeostasis and metabolism, in the central nervous system 
insulin can effectively modulate food intake and signal satiety. Insulin has also been 
shown to influence gonadotropin-releasing hormone (GnRH) in the hypothalamic 
neurons by increasing its expression and activity [95]. In PCOS, GnRH pulse 
frequency modifications and subsequent LH timing alterations have been suggested 
as another potential trigger to prevent inhibition of androgens and lead to their 
increased biosynthesis [96, 97]. This relationship illustrates the importance of the 
interplay between the neuroendocrine system, insulin, and androgen production in 
women with PCOS. Clinically, in a randomized controlled trial, women with PCOS 
treated for three months with Resveratrol, a natural polyphenol able to reduce 
androgen production via CYP17A1, showed a 30% reduction in fasting insulin and 
increased insulin sensitivity [98]. Together, these findings suggest the potential 
therapeutic importance of androgen targeted drugs to treat IR in PCOS patients.
The main target tissues of insulin action and subsequent insulin resistance and 
dysfunction include white adipose tissue, skeletal muscle, and the liver. Androgens 
play a significant role in each of these insulin-responsive target tissues in women.
7.1 Androgen actions on the adipose tissue
Androgens regulate several different aspects of adipose cell function and lipid 
accumulation and are themselves synthesized by the adipose tissue. Adipose tissue 
is known to play a role in whole-body insulin sensitivity, inflammation, and intra-
cellular stress. The adipose tissue is crucial for the storage of lipids, and adipocytes 
are the primary storage cells to serve this purpose. The adipose tissue can also 
release adipokines, like leptin and adiponectin, which may directly influence insu-
lin sensitivity, inflammatory response, fatty acid oxidation, sex steroids, and even 
energy expenditure. Several adipokines are dysregulated in PCOS [99]. Women 
with high androgens have been shown to display a fat distribution pattern more 
similar to men, with increased abdominal visceral adipose accumulation [100]. 
Although the expansion of the subcutaneous adipose depot is also associated with 
PCOS [101]. Additionally, after administration of androgen antagonists, women 
with PCOS were shown to lose visceral adiposity, which suggests that androgens 
have a role in fat distribution [102]. This increased adiposity is considered to be 
due to a hypertrophic adipocyte expansion compared to a hyperplasic response, 
which is more highly indicative of metabolic syndrome. Hypertrophy of adipo-
cytes is influenced by androgens directly by increasing visceral adipocyte mass. 
Women with PCOS have an increase in adipocyte size [103]. Androgens influence 
adipogenesis by limiting the differentiation of preadipocytes. In preadipocytes 
taken from the subcutaneous adipose depots of healthy women were shown to have 
impaired insulin-induced glucose uptake in response to testosterone [104]. This 
study suggests that androgens, via the androgen receptor, mediate insulin resistance 
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in adipocytes. Interestingly, the relationship between circulating testosterone and 
elevated fasting insulin in PCOS is independent of adiposity [105], supporting that 
insulin resistance is intrinsic to PCOS and may be mediated by hyperandrogenemia 
independently of obesity.
7.2 Androgens actions on the skeletal muscle
Glucose can be used as a primary fuel source in the skeletal muscle when insulin 
is high, instead of fatty acids, or can be stored in the form of glycogen for future 
periods of exercise. Glucose may enter the skeletal muscle in response to insulin by 
the specific cell surface transporter GLUT4. Skeletal muscle alone may show insulin 
resistance, which is defined as a reduced ability for glucose uptake and glycogen 
storage in response to insulin. Skeletal muscle serves as a primary organ for glucose 
disposal [87].
Several studies suggest that adiponectin and lower AMPK phosphorylation may 
be important in skeletal muscle-specific insulin resistance in PCOS [106], even 
in non-obese hyperandrogenic women. Adiponectin is an adipokine that has an 
inverse relationship with a degree of adiposity. Adiponectin has both insulin-sensi-
tizing properties, including skeletal muscle, and is decreased by androgens [107].
Androgens have been shown to alter lean muscle mass. Both healthy and women 
with PCOS who exercised using resistance strength training, which focuses on 
skeletal muscle contractions, along with aerobic training showed reduced fasting 
glucose concentration and serum testosterone profiles [108]. Together, this sug-
gests the potential to target the skeletal muscle to improve insulin-sensitive tissue 
sensitivity and improve hyperandrogenemia.
7.3 Androgens actions on the liver
Of crucial importance following a meal, glucose is allowed entry into the liver 
and stored as glycogen in the liver due to the effects of insulin. In a healthy adult, 
storage is especially important to help varying energy levels in the body to prevent 
blood glucose from changing rapidly between meals and allow it to be released 
when energy is needed.
Hyperandrogenemia in PCOS has been associated with several different 
disturbances of the liver. Alanine aminotransferase (ALT), often used as a clini-
cal biomarker of liver injury, has been shown in positive association to androgen 
levels in young women with PCOS [109]. Women with PCOS with high androgens 
display a distinct metabolic phenotype different than women with normal levels 
of androgens. There is evidence that women with PCOS are at an increased risk of 
developing a spectrum of nonalcoholic fatty liver disease, the most common liver 
disease. Women with PCOS and obesity have an increased risk for NAFLD [110]. 
Interestingly, even after adjusting for BMI, other PCOS cohorts have shown that 
hyperandrogenemic women with PCOS have a significantly higher liver fat than 
women with normal levels of androgens [111]. Those findings suggest that andro-
gens may be an independent risk factor for steatosis and the development of NAFLD.
8.  Pharmacological management of cardiometabolic complications  
in women with PCOS
Recent studies have shown that women with PCOS frequently report long delays 
in the syndrome’s diagnosis, dissatisfaction with information and care provided, 
and distrust in primary care providers’ opinions [112, 113]. Those patients’ concerns 
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with their diagnosis and health care providers are shocking, considering that PCOS 
is the most common endocrine disorder in reproductive-age women. We described 
below the current therapeutic options for the management of cardiometabolic 
complications in women with PCOS.
8.1 Oral contraceptives
Oral contraceptives (OCPs) are the first-line therapy in women with PCOS to 
improve their irregular menstrual cycles. OCPs reduce circulating androgens by 
suppression of Luteinizing Hormone and stimulation of sex hormone-binding 
globulin (SHBG), leading to a decrease in free testosterone plasma levels. In some 
women, OCPs can exacerbate hypertension and are associated with a 2-fold increase 
in the risk of cardiovascular diseases in the general female population [114]. 
Exogenous estrogens can stimulate the production of AGTN by the liver in female 
rats [115, 116], which theoretically could lead to higher levels of ANG II. OCPs are 
contraindicated for smokers due to the higher risk of cardiovascular diseases in 
this population [117]. OCPs do not seem to affect glucose and insulin homeostasis 
in healthy individuals [118]. However, the effect of OCPs on women with PCOS 
remains controversial, mainly due to the heterogeneity of the studies, as shown in 
a recent meta-analysis [119]. Furthermore, several clinical studies have suggested 
that the use of oral contraceptives may aggravate insulin resistance and worsen 
hyperglycemia in obese women with PCOS [120–123]. The long-term impact of 
OCPs in IR and cardiovascular diseases in women with PCOS remains unknown. 
Interestingly, previous use of OCPs was associated with an increased risk of devel-
opment of CVD in PCOS in a Danish study [33]. Prospective randomized long-term 
clinical trials analyzing the effect of OCPs on cardiovascular morbidity and mortal-
ity in women with PCOS, obese and lean, are lacking and desperately needed.
8.2 Androgen receptor blockers
Recommendations from the International evidence-based guideline for the 
assessment and management of Polycystic Ovary Syndrome [7] recommend that 
AR blockers be used mostly towards the dermatological manifestations of the 
syndrome, not the metabolic ones. AR blockers can be used in addition to OCPs and 
insulin sensitizers to ameliorate excessive hair growth or hirsutism. Antiandrogen 
monotherapy is not recommended because of its teratogenic potential [124]. In 
the US, the AR blocker most commonly used in the clinic is spironolactone [124]. 
Spironolactone is also a progesterone and mineralocorticoid receptor blocker. 
Blockade of the mineralocorticoid receptor causes a diuretic effect that potentially 
can cause serious side effects such as hyperkalemia and hypotension [124]. Other 
potent antiandrogens are flutamide and cyproterone acetate. Cyproterone acetate 
is not currently available in the US and recently has been linked to an increased risk 
of meningioma among high dose users [125]. Flutamide use has been associated 
with severe hepatoxicity, and it is not FDA-approved for use in women with PCOS. 
Bicalutamide, an androgen receptor blocker, has been used in combination with 
OCPs in a study where hirsutism was the primary endpoint [126]. Safe, effective, 
and specific AR blockers are necessary to positively impact the management of the 
cardiometabolic risk factors in women with PCOS.
8.3 Insulin sensitizers
Metformin is the most frequent insulin sensitizer agent used in women with 
PCOS [124, 127]. Obesity exacerbates the IR in women with PCOS, and weight loss 
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in women with PCOS ameliorates it. However, weight loss is very difficult to achieve 
and sustain. Since insulin resistance is present in obese and lean women with PCOS, 
it has been proposed to be the key factor in mediating the adverse cardiovascular 
risk profile observed in PCOS subjects. Metformin has been used for years to treat 
insulin resistance in women with PCOS. The effectiveness of metformin to improve 
IR and prevent T2DM in women with PCOS is unclear. Metformin reduces the 
risk of progression from insulin resistance to T2DM in only 30% of patients in the 
Diabetes Prevention Trial [128]. Metformin can lower testosterone levels; thereby, 
some of the beneficial effects in women with PCOS may be due to lowering their 
androgen levels [129]. A recent metanalysis showed no effect of metformin on 
indexes of fasting insulin, homeostasis model assessment of insulin resistance, sex 
hormone-binding globulin, high-density lipoprotein cholesterol, total cholesterol, 
triglycerides, fasting blood glucose, and androstenedione in overweight women 
with PCOS [130]. Long-term prospective randomized controlled trials assessing 
the effect of metformin on cardiovascular morbidity and mortality in women with 
PCOS are not available at present.
8.4 Incretins
Glucagon-like peptide-1 (GLP-1) is an incretin that potentiates the food-
mediated release of insulin leading to a decrease in plasma glucose levels and 
delaying gastric emptying, and exerting satiety effects. Several short-term clinical 
trials showed that administration of GLP-1 receptor agonists caused significant 
improvement in metabolic abnormalities and also cause weight loss in women with 
PCOS [131]. Similar beneficial effects of GLP-1 were observed in hyperandrogenic 
female rats [132]. In contrast, we recently reported that administration of the GLP-1 
receptor agonist (GLP-1 RA) liraglutide to a model of postmenopausal PCOS, elicits 
several beneficial metabolic effects but the BP-lowering effect of GLP-1 RA was 
blunted compared with control rats [64]. These results suggest that GLP-1 RA treat-
ment could improve DHT-induced metabolic and BP abnormalities in reproductive-
aged PCOS. It is possible to hypothesize that GLP-1 RA’s BP-lowering effect in 
PCOS animals could be mediated by estrogens, which are significantly decreased in 
postmenopausal PCOS rodents, leading to the lack of effect in those aging animals. 
This concept of a role for estrogens in the age-differential effect of GLP-1 RA in BP 
regulation in PCOS is an exciting hypothesis that needs to be tested.
8.5 SGLT2 inhibitors
Among therapies in clinical trials for women with PCOS are the sodium-glucose 
cotransporter-2 inhibitors (SGLT2i), which are antidiabetic agents. SGLT2i has 
recently been shown to be superior to metformin for weight loss in women with PCOS 
[133]. Additionally, SGLT2i is cardioprotective in patients with T2DM or with heart 
failure [134]. For example, in the EMPA-REG trial, SGLT2i reduced the relative risk of 
cardiovascular death by 38% in patients with T2DM on the background of the block-
ade of the renin-angiotensin system (RAS) [135]. A possible mechanism to explain 
why SGLT2i has dramatic cardiovascular protection includes its interactions with the 
RAS, which is affected by sex steroids and is a major regulator of BP [45, 136].
9. Conclusions
PCOS, the most common endocrine disorder in reproductive-aged women, is 
associated with increases in BP and IR. Excess of androgens, a cardinal feature of 
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